[1] |
Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities[J]. Anticancer Drugs, 2009,20(10):851⁃855. doi: 10.1097/CAD.0b013e3283330590.
|
[2] |
Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin⁃based chemotherapy for EGFR mutation⁃positive lung adenocarcinoma (LUX⁃Lung 3 and LUX⁃Lung 6): analysis of overall survival data from two randomised, phase 3 trials[J]. Lancet Oncol, 2015,16(2):141⁃151. doi: 10.1016/S1470⁃2045(14)71173⁃8.
|
[3] |
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors[J]. Nat Rev Cancer, 2006,6(10):803⁃812. doi: 10. 1038/nrc1970.
|
[4] |
Tsimboukis S, Merikas I, Karapanagiotou EM, et al. Erlotinib⁃induced skin rash in patients with non⁃small⁃cell lung cancer: pathogenesis, clinical significance, and management[J]. Clin Lung Cancer, 2009,10(2):106⁃111. doi: 10.3816/CLC.2009.n. 013.
|
[5] |
Lalchandani UR, Sahai V, Hersberger K, et al. A radiologist′s guide to response evaluation criteria in solid tumors[J]. Curr Probl Diagn Radiol, 2019,48(6):576⁃585. doi: 10.1067/j.cpradiol. 2018.07.016.
|
[6] |
Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0[J]. J Am Acad Dermatol, 2012,67(5):1025⁃1039. doi: 10.1016/j.jaad.2012.02.010.
|
[7] |
Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets[J]. Trends Mol Med, 2007,13(12):527⁃534. doi: 10.1016/j.molmed. 2007.10.002.
|
[8] |
Bianchini D, Jayanth A, Chua YJ, et al. Epidermal growth factor receptor inhibitor⁃related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker[J]. Clin Colorectal Cancer, 2008,7(1):33⁃43. doi: 10.3816/CCC.2008.n.005.
|
[9] |
Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management[J]. Dermatol Res Pract, 2014,2014:734249[2020⁃08⁃05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958662/. doi: 10.1155/2014/734249.
|
[10] |
Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial[J]. J Clin Oncol, 2004,22(13):2610⁃2616. doi: 10.1200/JCO.2004.12.040.
|
[11] |
Kudo K, Hotta K, Bessho A, et al. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR⁃mutant non⁃small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience[J]. Cancer Chemother Pharmacol, 2016,77(5):1005⁃1009. doi: 10.1007/s00280⁃015⁃2910⁃9.
|
[12] |
Peng Y, Li Q, Zhang J, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors[J]. Biosci Trends, 2019,12(6):537⁃552. doi: 10.5582/bst.2018.01246.
|